tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

OKUR Stock Latest News

VTI ETF News, 10/9/2025
Market NewsVTI ETF News, 10/9/2025
10d ago
LVO
VTI
VTI ETF News, 10/8/2025
PremiumMarket News
VTI ETF News, 10/8/2025
11d ago
LVO
VTI
VTI ETF News, 10/7/2025
PremiumMarket News
VTI ETF News, 10/7/2025
12d ago
VTI
BCAB
Buy Recommendation for OnKure Therapeutics Based on Strategic Development of PI3Kα Programs and Promising OKI-219 Trial Results
PremiumRatings
Buy Recommendation for OnKure Therapeutics Based on Strategic Development of PI3Kα Programs and Promising OKI-219 Trial Results
1M ago
OKUR
OnKure Therapeutics Advances Cancer Drug Development
PremiumCompany Announcements
OnKure Therapeutics Advances Cancer Drug Development
2M ago
OKUR
OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)
PremiumThe FlyOnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)
2M ago
OKUR
OnKure Therapeutics’ Strategic Delay and Confidence in PI3Ka Inhibitor Development Supports Buy Rating
Premium
Ratings
OnKure Therapeutics’ Strategic Delay and Confidence in PI3Ka Inhibitor Development Supports Buy Rating
4M ago
OKUR
OnKure Therapeutics Updates on PI3Kα Inhibitor Progress
Premium
Company Announcements
OnKure Therapeutics Updates on PI3Kα Inhibitor Progress
4M ago
8K
OKUR
Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position
PremiumRatings
Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position
5M ago
OKUR
OnKure Elects Directors at Annual Stockholder Meeting
PremiumCompany Announcements
OnKure Elects Directors at Annual Stockholder Meeting
5M ago
8K
OKUR
One new option listing and nine option delistings on May 19th
PremiumThe Fly
One new option listing and nine option delistings on May 19th
5M ago
J
DFS
Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics
PremiumRatings
Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics
5M ago
OKUR
OnKure Therapeutics Reports Q1 2025 Progress and Financials
PremiumCompany AnnouncementsOnKure Therapeutics Reports Q1 2025 Progress and Financials
5M ago
OKUR
OnKure Therapeutics reports Q1 EPS ($1.19), consensus ($1.38)
Premium
The Fly
OnKure Therapeutics reports Q1 EPS ($1.19), consensus ($1.38)
6M ago
OKUR
OnKure Therapeutics sees cash runway into 4Q26
Premium
The Fly
OnKure Therapeutics sees cash runway into 4Q26
6M ago
OKUR
OnKure Therapeutics initiated with an Outperform at Evercore ISI
PremiumThe Fly
OnKure Therapeutics initiated with an Outperform at Evercore ISI
6M ago
OKUR
OnKure Therapeutics price target lowered to $34 from $40 at H.C. Wainwright
PremiumThe Fly
OnKure Therapeutics price target lowered to $34 from $40 at H.C. Wainwright
7M ago
OKUR
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025
PremiumRatings
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025
7M ago
OKUR
Oppenheimer biotech analyst holds an analyst/industry conference call
PremiumThe Fly
Oppenheimer biotech analyst holds an analyst/industry conference call
7M ago
AZN
LLY
Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects
PremiumRatingsOptimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects
7M ago
OKUR
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies
Premium
Company Announcements
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies
7M ago
OKUR
OnKure Therapeutics Reports Progress and Financials
Premium
Company Announcements
OnKure Therapeutics Reports Progress and Financials
7M ago
OKUR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >